Emerging Technology in Treatment of Valvular Heart Disease

Dr. Paul Mahoney, from the Structural Heart Program at Sentara, discusses new frontiers in TAVR to include new technology, new techniques and new indications. 


November 10, 2021

Created by


Related Presenters

Paul D. Mahoney, MD, FACC

Paul D. Mahoney, MD, FACC

Medical Director - Structural Heart Program - Sentara Cardiology Specialists

Dr. Paul Mahoney serves as the Medical Director of the Sentara Structural Heart Program, he has a particular focus on the diagnosis and treatment of structural heart disease. He performs interventions such as transcatheter aortic valve replacement...

View full profile